Pharmadrug Inc. (TSE:PHRX) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PharmaDrug’s subsidiary Sairiyo Therapeutics has wrapped up the clinical and regulatory preparations necessary for a Phase 1 study in Australia, targeting the use of PD-001, a reformulated version of cepharanthine, for infectious diseases and cancer treatment. The company is poised to submit for ethical approval and looks forward to benefitting from Australia’s R&D tax incentives, with an eye on future FDA trials in the United States. PD-001 offers improved oral bioavailability over traditional cepharanthine, potentially enhancing therapeutic outcomes for patients.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.